Ligand non-competitive GITR antibody prevents formation of the obligatory signal-triggering GITRL: GITR stoichiometry
Year: 2025
Type: article
Abstract: The prevalence of autoimmune diseases such as inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) is increasing. Glucocorticoid-induced TNFR-related protein (GITR), a TNF receptor superfamily (TNFRSF) member, is activated by GITR-ligand (GITRL). GITR signaling is pathogenic in models of RA and IBD, leading to lymphocyte proliferation and secretion of pro-inflammatory cytokines. Despite promising preclinical data, GITR neutralization in autoimmune diseases remains under-explored, due to challenges in avoiding antibody-mediated GITR activation. Therefore, we developed a human GITR-specific antibody that inhibits GITRL-mediated GITR-signaling, while preserving the GITRL epitope on GITR. The antibody strongly inhibited GITR signaling in the in vitro assays via a novel mechanism of disrupting downstream higher-order structures rather than direct blocking of GITR binding. Even though the antibody did not demonstrate efficacy in an NSG human skin graft transplant model, this general mechanism might be a viable therapeutic intervention for other TNFRSF members relying more significantly on soluble ligands.
Source: Scientific Reports
Authors: Jing Yan, Jessica Min-DeBartolo, Ching-Shin Huang, M. Nusrat Sharif, Li Li, Susan Fish, Corey Dower, Denise Murphy, Tatyana Andreyeva, Heng Liu, Xinbing Han, Wei Zheng, Jot Hui Ooi, Jason Edmonds, Ting Chen, Zachary Maben, Chad R. Stevens, Polina Goihberg, Malgorzata Nocula-Lugowska, Steven M Evans, Lidia Mosyak, Kerry Kelleher, Caitlyn Dickinson, Martin Hegen, Aaron Winkler, Fridrik Karlsson
Institution: Pfizer (United States)
Language: English
Topic: T-cell and B-cell Immunology
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,690
Funder: Pfizer
OpenAlex ID: W4417524009
